Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts
The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics m...
Gespeichert in:
| Veröffentlicht in: | Clinical gastroenterology and hepatology 2020-08, Vol.18 (9), p.2134-2135 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2135 |
|---|---|
| container_issue | 9 |
| container_start_page | 2134 |
| container_title | Clinical gastroenterology and hepatology |
| container_volume | 18 |
| creator | Allocca, Mariangela Fiorino, Gionata Zallot, Camille Furfaro, Federica Gilardi, Daniela Radice, Simona Danese, Silvio Peyrin-Biroulet, Laurent |
| description | The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes. |
| doi_str_mv | 10.1016/j.cgh.2020.04.071 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7191273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356520306169</els_id><sourcerecordid>2398159100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-49736422f7800629111cb198c0f449a5d664fa8db22adebcb0de81f73513e2d53</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhUcIREvhAdggL9nM4Gt7_oSEVFJaIhXKAthaHvtO4mjGbm2nKG9fh4QKNqx8JZ9z7rG_ongNtAIKzbtNpVfrilFGKyoq2sKT4hRqwcq2BfH0OPO6qU-KFzFuKGW96NvnxQlnvKEdwGkxL522Bp1Gopwh31RKGFwkfiSLm5_LixJ6cj57tyJLN05qnlXyYUc--l84kQsbUUXcuyy6FMll8DNJayRfldO734lf7KQcWfi1Dym-LJ6Naor46nieFT8uP31ffC6vb66Wi_PrUosaUplL8kYwNrYdpQ3rAUAP0HeajkL0qjZNI0bVmYExZXDQAzXYwdjyGjgyU_Oz4sMh93Y7zGh0LhfUJG-DnVXYSa-s_PfG2bVc-XvZQg-s5Tng7TEg-LstxiRnGzVO-S3ot1Ey3ndQ90BplsJBqoOPMeD4uAao3GOSG5kxyT0mSYXMmLLnzd_9Hh1_uGTB-4MA8y_dWwwyarunZGxAnaTx9j_xD7ggorM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398159100</pqid></control><display><type>article</type><title>Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Allocca, Mariangela ; Fiorino, Gionata ; Zallot, Camille ; Furfaro, Federica ; Gilardi, Daniela ; Radice, Simona ; Danese, Silvio ; Peyrin-Biroulet, Laurent</creator><creatorcontrib>Allocca, Mariangela ; Fiorino, Gionata ; Zallot, Camille ; Furfaro, Federica ; Gilardi, Daniela ; Radice, Simona ; Danese, Silvio ; Peyrin-Biroulet, Laurent</creatorcontrib><description>The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2020.04.071</identifier><identifier>PMID: 32360811</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Betacoronavirus - isolation & purification ; Coronavirus Infections - epidemiology ; COVID-19 ; France - epidemiology ; Humans ; Immunocompromised Host ; Incidence ; Inflammatory Bowel Diseases - complications ; Italy - epidemiology ; Pandemics ; Pneumonia, Viral - epidemiology ; Registries - statistics & numerical data ; SARS-CoV-2</subject><ispartof>Clinical gastroenterology and hepatology, 2020-08, Vol.18 (9), p.2134-2135</ispartof><rights>2020 AGA Institute</rights><rights>Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><rights>2020 by the AGA Institute. 2020 AGA Institute</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-49736422f7800629111cb198c0f449a5d664fa8db22adebcb0de81f73513e2d53</citedby><cites>FETCH-LOGICAL-c451t-49736422f7800629111cb198c0f449a5d664fa8db22adebcb0de81f73513e2d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1542356520306169$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32360811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allocca, Mariangela</creatorcontrib><creatorcontrib>Fiorino, Gionata</creatorcontrib><creatorcontrib>Zallot, Camille</creatorcontrib><creatorcontrib>Furfaro, Federica</creatorcontrib><creatorcontrib>Gilardi, Daniela</creatorcontrib><creatorcontrib>Radice, Simona</creatorcontrib><creatorcontrib>Danese, Silvio</creatorcontrib><creatorcontrib>Peyrin-Biroulet, Laurent</creatorcontrib><title>Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes.</description><subject>Betacoronavirus - isolation & purification</subject><subject>Coronavirus Infections - epidemiology</subject><subject>COVID-19</subject><subject>France - epidemiology</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Incidence</subject><subject>Inflammatory Bowel Diseases - complications</subject><subject>Italy - epidemiology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Registries - statistics & numerical data</subject><subject>SARS-CoV-2</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1uEzEUhUcIREvhAdggL9nM4Gt7_oSEVFJaIhXKAthaHvtO4mjGbm2nKG9fh4QKNqx8JZ9z7rG_ongNtAIKzbtNpVfrilFGKyoq2sKT4hRqwcq2BfH0OPO6qU-KFzFuKGW96NvnxQlnvKEdwGkxL522Bp1Gopwh31RKGFwkfiSLm5_LixJ6cj57tyJLN05qnlXyYUc--l84kQsbUUXcuyy6FMll8DNJayRfldO734lf7KQcWfi1Dym-LJ6Naor46nieFT8uP31ffC6vb66Wi_PrUosaUplL8kYwNrYdpQ3rAUAP0HeajkL0qjZNI0bVmYExZXDQAzXYwdjyGjgyU_Oz4sMh93Y7zGh0LhfUJG-DnVXYSa-s_PfG2bVc-XvZQg-s5Tng7TEg-LstxiRnGzVO-S3ot1Ey3ndQ90BplsJBqoOPMeD4uAao3GOSG5kxyT0mSYXMmLLnzd_9Hh1_uGTB-4MA8y_dWwwyarunZGxAnaTx9j_xD7ggorM</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Allocca, Mariangela</creator><creator>Fiorino, Gionata</creator><creator>Zallot, Camille</creator><creator>Furfaro, Federica</creator><creator>Gilardi, Daniela</creator><creator>Radice, Simona</creator><creator>Danese, Silvio</creator><creator>Peyrin-Biroulet, Laurent</creator><general>Elsevier Inc</general><general>by the AGA Institute</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200801</creationdate><title>Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts</title><author>Allocca, Mariangela ; Fiorino, Gionata ; Zallot, Camille ; Furfaro, Federica ; Gilardi, Daniela ; Radice, Simona ; Danese, Silvio ; Peyrin-Biroulet, Laurent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-49736422f7800629111cb198c0f449a5d664fa8db22adebcb0de81f73513e2d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Betacoronavirus - isolation & purification</topic><topic>Coronavirus Infections - epidemiology</topic><topic>COVID-19</topic><topic>France - epidemiology</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Incidence</topic><topic>Inflammatory Bowel Diseases - complications</topic><topic>Italy - epidemiology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Registries - statistics & numerical data</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allocca, Mariangela</creatorcontrib><creatorcontrib>Fiorino, Gionata</creatorcontrib><creatorcontrib>Zallot, Camille</creatorcontrib><creatorcontrib>Furfaro, Federica</creatorcontrib><creatorcontrib>Gilardi, Daniela</creatorcontrib><creatorcontrib>Radice, Simona</creatorcontrib><creatorcontrib>Danese, Silvio</creatorcontrib><creatorcontrib>Peyrin-Biroulet, Laurent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allocca, Mariangela</au><au>Fiorino, Gionata</au><au>Zallot, Camille</au><au>Furfaro, Federica</au><au>Gilardi, Daniela</au><au>Radice, Simona</au><au>Danese, Silvio</au><au>Peyrin-Biroulet, Laurent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>18</volume><issue>9</issue><spage>2134</spage><epage>2135</epage><pages>2134-2135</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32360811</pmid><doi>10.1016/j.cgh.2020.04.071</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-3565 |
| ispartof | Clinical gastroenterology and hepatology, 2020-08, Vol.18 (9), p.2134-2135 |
| issn | 1542-3565 1542-7714 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7191273 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Betacoronavirus - isolation & purification Coronavirus Infections - epidemiology COVID-19 France - epidemiology Humans Immunocompromised Host Incidence Inflammatory Bowel Diseases - complications Italy - epidemiology Pandemics Pneumonia, Viral - epidemiology Registries - statistics & numerical data SARS-CoV-2 |
| title | Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20Patterns%20of%20COVID-19%20Among%20Inflammatory%20Bowel%20Disease%20Patients%20From%20the%20Nancy%20and%20Milan%20Cohorts&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Allocca,%20Mariangela&rft.date=2020-08-01&rft.volume=18&rft.issue=9&rft.spage=2134&rft.epage=2135&rft.pages=2134-2135&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2020.04.071&rft_dat=%3Cproquest_pubme%3E2398159100%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2398159100&rft_id=info:pmid/32360811&rft_els_id=S1542356520306169&rfr_iscdi=true |